J Cancer 2018; 9(18):3295-3302. doi:10.7150/jca.25691 This issue Cite

Research Paper

Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis

Ruonan Yang, Qian Chang, Xianchun Meng, Nan Gao, Wanhai Wang

Clinical Laboratory, First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, People's Republic of China.

Citation:
Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer 2018; 9(18):3295-3302. doi:10.7150/jca.25691. https://www.jcancer.org/v09p3295.htm
Other styles

File import instruction

Abstract

Systemic immune-inflammation index (SII), on the basis of lymphocyte, neutrophil and platelet counts had been published to be a good prognostic factor in multiple cancers. Nevertheless, the prognostic value of SII in cancer patients remains inconsistent. Therefore, we carried out a meta-analysis to evaluate the prognostic value of SII in these patients with cancer. A total of 22 articles with 7657 patients enrolled in this meta-analysis. The combined result revealed that a high SII was evidently correlated with poor overall survival (OS) (HR=1.69, 95%CI=1.42-2.01, p<0.001), poor time to recurrent (TTR) (HR=1.87, p<0.001) , poor progress-free survival (PFS) (HR=1.61, p=0.012) ,poor cancer-specific survival (CSS) (HR=1.44, p=0.027) , poor relapse-free survival (RFS) (HR=1.66, p=0.025) and poor disease-free survival (DFS) (HR=2.70, p<0.001) in patients with cancers. Subgroup analysis indicated that SII over the cutoff value could predict worse overall survival in Hepatocellular carcinoma (p<0.001), Gastric cancer (p=0.005), Esophageal Squamous Cell Carcinoma (p=0.013), Urinary system cancer (p<0.001), Small cell lung cancer (p<0.001), Non-Small cell lung cancer (p<0.001) and Acral Melanoma (p<0.001). The largest effect size was observed in the Hepatocellular carcinoma (HR=2.11). In addition, these associations did not vary significantly by the cutoff value, sample size and ethnicity. Therefore, high SII may be a potential prognostic marker in patients with various cancers and associated with the poor overall outcomes.

Keywords: Systemic immune-inflammation index, cancer, prognosis, meta-analysis


Citation styles

APA
Yang, R., Chang, Q., Meng, X., Gao, N., Wang, W. (2018). Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. Journal of Cancer, 9(18), 3295-3302. https://doi.org/10.7150/jca.25691.

ACS
Yang, R.; Chang, Q.; Meng, X.; Gao, N.; Wang, W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J. Cancer 2018, 9 (18), 3295-3302. DOI: 10.7150/jca.25691.

NLM
Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer 2018; 9(18):3295-3302. doi:10.7150/jca.25691. https://www.jcancer.org/v09p3295.htm

CSE
Yang R, Chang Q, Meng X, Gao N, Wang W. 2018. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 9(18):3295-3302.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image